Precision medicine for cancer is an approach that matches treatments to the specific genetic and molecular makeup of a person’s tumor, rather than treating all cancers of the same type with the same therapy. Every person’s cancer is driven by a distinct combination of gene mutations and cellular changes, which means a treatment that shrinks one person’s lung tumor may do nothing for another person with the same diagnosis. Precision oncology uses testing to identify those differences and select therapies most likely to work for each individual.
How It Differs From Traditional Treatment
Standard chemotherapy works by killing rapidly dividing cells throughout the body, which is why it causes widespread side effects like hair loss, nausea, and immune suppression. Targeted treatments developed through precision medicine attack specific molecular features of cancer cells. Because they’re designed to hit particular targets rather than broadly toxic to all fast-growing cells, they tend to cause fewer and less severe side effects than chemotherapy.
The practical difference for patients is significant. In a study of late-stage cancer patients, those who received a therapy matched to their tumor’s molecular profile survived a median of 15.7 months, compared to roughly 6 months for patients who didn’t receive matched treatment. That’s 2.6 times longer survival, and the benefit held up even after accounting for differences in how sick patients were or how many places their cancer had spread.
What Happens During Tumor Testing
Precision medicine starts with analyzing your cancer’s DNA. This typically involves a biopsy sample that undergoes multi-gene panel sequencing, a technology that reads hundreds of genes at once to look for mutations, gene fusions, and other alterations driving the cancer’s growth. The most common alterations used as cancer biomarkers are small changes in individual genes, sometimes involving just a single letter of the genetic code.
The results identify which molecular “switches” are turned on in your specific tumor. Some of the most well-known targets include:
- HER2 amplification in breast, ovarian, bladder, pancreatic, and stomach cancers
- EGFR mutations in non-small cell lung cancer
- BRAF V600 mutations in melanoma, colorectal cancer, and lung cancer
- KRAS mutations in colorectal and lung cancers
- ALK gene rearrangements in lung cancer and certain lymphomas
- NTRK gene fusions in any solid tumor, regardless of where it started
That last one is worth noting. NTRK fusions are rare, but when found, the same targeted drug can work whether the cancer is in the thyroid, colon, lung, or elsewhere. This is a fundamentally different way of categorizing cancer: by its molecular driver rather than its location in the body.
Biomarkers That Guide Immunotherapy
Precision medicine also determines whether immunotherapy is likely to help. Immunotherapy drugs work by removing the “brakes” that cancer cells put on the immune system, but they don’t work equally well for everyone. Several biomarkers help predict who will benefit most.
PD-L1 expression is one of the most commonly tested. In urothelial (bladder) cancer patients treated with an immune checkpoint inhibitor, those with high PD-L1 levels had an objective response rate of 39%, compared to just 11% in patients with very low levels. Tumor mutational burden, which measures how many mutations a tumor carries overall, is another predictor. Cancers with more mutations tend to produce more abnormal proteins that the immune system can recognize, making immunotherapy more effective. Patients who have both high PD-L1 expression and high tumor mutational burden tend to do best of all.
A third biomarker, called microsatellite instability, reflects a broken DNA repair system within tumor cells. Cancers with high microsatellite instability accumulate mutations rapidly, which again makes them more visible to the immune system. This marker has proven useful in colon cancer, endometrial cancer, and increasingly in lung cancer for predicting immunotherapy response.
Liquid Biopsies and Ongoing Monitoring
A growing part of precision oncology involves liquid biopsies, which are blood draws that detect fragments of tumor DNA circulating in the bloodstream. Unlike a traditional tissue biopsy, which requires a needle or surgery, a liquid biopsy is minimally invasive and can be repeated over time.
These tests serve several roles. In patients with localized cancer who’ve had surgery, liquid biopsies can detect tiny amounts of residual disease that imaging can’t pick up, helping doctors decide whether additional treatment is needed. In patients with metastatic cancer, repeated liquid biopsies can reveal early signs that a treatment is working or, just as importantly, that the tumor is developing resistance before it shows up on a scan. They also offer a window into the tumor’s evolving genetics without requiring another tissue biopsy, which matters when tumors are in hard-to-reach locations.
Why Targeted Therapies Eventually Stop Working
One of the biggest challenges in precision oncology is that most targeted therapies eventually lose effectiveness. When a drug blocks a specific molecular pathway, surviving cancer cells face intense pressure to find workarounds. Over time, some cells acquire new genetic changes that let them bypass the drug’s effects and start growing again.
Research from the National Cancer Institute has shed light on one mechanism behind this. When treated with targeted drugs, some cancer cells undergo a dramatic process where chunks of DNA break out of chromosomes and form small circular molecules called extrachromosomal DNAs. Cancer cells can produce up to 100 copies of these circular molecules, massively amplifying genes that drive resistance. A cellular repair process called non-homologous end-joining appears to be critical for stitching these resistance-driving molecules together.
This discovery has opened a potential counterstrategy. In mice with melanoma, blocking the repair process with an experimental drug delayed or prevented resistance to targeted therapy. A clinical trial is being developed to test this approach in melanoma patients, combining the targeted therapy with the resistance-blocking drug from the start.
New Clinical Trial Designs
Precision medicine has changed not just how cancer is treated but how treatments are tested. Two newer trial designs, basket trials and umbrella trials, reflect the shift toward molecular-guided care.
A basket trial tests one targeted therapy across multiple different cancer types that share the same molecular alteration. For example, if a drug targets a specific gene fusion, the trial might enroll patients with lung cancer, thyroid cancer, and sarcoma, grouping them by their shared mutation rather than by where the cancer originated. An umbrella trial does the opposite: it focuses on a single cancer type but divides patients into subgroups based on different molecular targets, testing a different matched therapy in each arm. Both designs operate under a single master protocol with standardized procedures, which makes them faster and more efficient than running separate trials for each cancer type and each drug.
Access and Cost Considerations
Multi-gene panel sequencing is increasingly available at major cancer centers and through commercial testing companies, but access remains uneven. Insurance coverage varies by country, by insurer, and sometimes by cancer type. National recommendations for using multi-gene panels generally don’t include explicit cost-effectiveness guidelines, which contributes to inconsistent reimbursement policies.
A population-based study in Canada found that multi-gene panel testing for advanced lung cancer was cost-effective at standard thresholds, with an 84% probability of being worth the investment when measured against conventional benchmarks. The incremental cost was modest, roughly $3,500 Canadian dollars over three years. But the clinical benefit in that study was small on a population level, reflecting the reality that only a subset of patients will have a targetable mutation, and not all of those will respond to matched therapy. The value of testing is highest for cancers where multiple targetable mutations exist and approved therapies are available for each one, like non-small cell lung cancer.
The Role of AI in Matching Treatments
As the amount of molecular data generated per patient grows, artificial intelligence is becoming a practical tool for interpreting it. AI systems can analyze genomic sequencing results alongside pathology images, blood markers, and clinical records to identify patterns that would take human specialists much longer to find. Major cancer centers are developing AI agents that can independently sift through large clinical and genomic datasets to surface treatment-relevant insights. The goal is shifting from reactive analysis (what’s happening now) to predictive guidance (what’s likely to happen next), helping oncologists anticipate which patients are at risk for resistance or recurrence and adjust treatment before problems emerge on imaging.